Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2002 07:34 ET | Source: Active Biotech

New Results from Active Biotech's SAIK-MS Project

LUND, Sweden, Oct. 10, 2002 (PRIMEZONE) -- At the Medicon Valley BioConference in Malmo, Active Biotech (Other OTC:ACTBF) today published new data about the development of its SAIK-MS substance for...
October 10, 2002 07:01 ET | Source: Active Biotech

New results from Active Biotech’s SAIK-MS project

Data was presented showing that oral treatment with SAIK-MS (Laquinimod) in tablet form inhibits the progress of disease in various MS-like animal models. Laquinimod is the generic name given by the...
October 10, 2002 06:55 ET | Source: Active Biotech

Nya resultat rörande Active Biotechs projekt SAIK-MS

Vid konferensen presenterades data som visar att oral behandling i tablettform med SAIK-MS (Laquinimod) hämmar utvecklingen av olika MS-liknande sjukdomsmodeller hos djur. Laquinimod är det generiska...
August 15, 2002 03:52 ET | Source: Active Biotech

Active Biotech Interim Report April-June 2002

The full Interim Report including tables is available to download from the enclosed link....
August 15, 2002 03:24 ET | Source: Active Biotech

Active Biotech Kvartalsrapport April-juni 2002

Hela rapporten inklusive tabeller finns att ladda ner från medföljande länk....
August 12, 2002 05:16 ET | Source: Active Biotech

Teleconference - Active Biotech AB

To listen to the teleconference live, please call +44 20 8240 8243. To view the presentation: please visit www.activebiotech.com. To listen to the conference and to view the...
August 12, 2002 05:12 ET | Source: Active Biotech

Telekonferens - Active Biotech AB

För att lyssna på telefonkonferensen, v.v. ring +44 20 8240 8243 För att samtidigt följa presentationen: besök www.activebiotech.com. Vill ni gå in och lyssna och se på...
June 24, 2002 05:38 ET | Source: Active Biotech

Active Biotech has selected a new Candidate Drug for the treatment of SLE

Active Biotech has selected a Candidate Drug, ABR-215757, within the SLE project for further development into clinical phase. The SLE project is included in the company's "competence...
June 24, 2002 05:22 ET | Source: Active Biotech

Active Biotech har valt läkemedelskandidat för SLE-projektet

SLE-projektet ingår i företagets s.k. "Q-kompetensplattform". Ytterligare projekt baserade på denna kompetens är SAIK-MS, som befinner sig i klinisk utveckling Fas II för behandling av multipel...
May 31, 2002 08:11 ET | Source: Active Biotech

Active Biotech’s drug for the treatment of Multiple Sclerosis

Active Biotech’s drug for the treatment of MS, SAIK-MS, is currently in clinical Phase II, where the efficacy is verified on MS patients. The ongoing study is a multi-center study where 180...